These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16544172)

  • 21. The Remission Clinic approach to halt the progression of kidney disease.
    ;
    J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy.
    Hollenberg NK; Raij L
    Arch Intern Med; 1993 Nov; 153(21):2426-35. PubMed ID: 8215747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease.
    Epstein M
    Blood Press Suppl; 1995; 2():108-12. PubMed ID: 7582066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition.
    Wei A; Burns GC; Williams BA; Mohammed NB; Visintainer P; Sivak SL
    Kidney Int; 2003 Oct; 64(4):1462-71. PubMed ID: 12969167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes.
    Schievink B; Kröpelin T; Mulder S; Parving HH; Remuzzi G; Dwyer J; Vemer P; de Zeeuw D; Lambers Heerspink HJ
    Diabetes Obes Metab; 2016 Jan; 18(1):64-71. PubMed ID: 26434564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone marrow transplant nephropathy successfully treated with angiotensin-converting enzyme inhibitor.
    Ichida S; Okada K; Itoh M; Okada R; Katoh N; Kasai M; Yuzawa Y
    Clin Exp Nephrol; 2006 Mar; 10(1):78-81. PubMed ID: 16544182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F; Rangoonwala B
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T; Najafi I; Salimi BH; Broomand B
    Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methods of cardio-renal protection in non-diabetic chronic nephropathies.
    Ruggenenti P; Remuzzi G
    Rocz Akad Med Bialymst; 2004; 49():116-23. PubMed ID: 15631326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progressive renal insufficiency: the role of angiotensin converting enzyme inhibitors.
    Savage S; Schrier RW
    Adv Intern Med; 1992; 37():85-101. PubMed ID: 1558007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.